139 related articles for article (PubMed ID: 37798397)
1. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.
Omar AM; Abdulmalik O; El-Say KM; Ghatge MS; Cyril-Olutayo M; Paredes S; Al-Awadh M; El-Araby ME; Safo MK
Chem Biol Drug Des; 2024 Jan; 103(1):e14371. PubMed ID: 37798397
[TBL] [Abstract][Full Text] [Related]
2. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS
Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ
J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482
[TBL] [Abstract][Full Text] [Related]
6. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
Abdulmalik O; Pagare PP; Huang B; Xu GG; Ghatge MS; Xu X; Chen Q; Anabaraonye N; Musayev FN; Omar AM; Venitz J; Zhang Y; Safo MK
Sci Rep; 2020 Nov; 10(1):20277. PubMed ID: 33219275
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
Safo MK; Kato GJ
Hematol Oncol Clin North Am; 2014 Apr; 28(2):217-31. PubMed ID: 24589263
[TBL] [Abstract][Full Text] [Related]
8. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
Oder E; Safo MK; Abdulmalik O; Kato GJ
Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
[TBL] [Abstract][Full Text] [Related]
9. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
Pagare PP; Ghatge MS; Musayev FN; Deshpande TM; Chen Q; Braxton C; Kim S; Venitz J; Zhang Y; Abdulmalik O; Safo MK
Bioorg Med Chem; 2018 May; 26(9):2530-2538. PubMed ID: 29655608
[TBL] [Abstract][Full Text] [Related]
10. Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.
Pagare PP; Rastegar A; Abdulmalik O; Omar AM; Zhang Y; Fleischman A; Safo MK
Expert Opin Ther Pat; 2022 Feb; 32(2):115-130. PubMed ID: 34657559
[TBL] [Abstract][Full Text] [Related]
11. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.
Omar AM; Mahran MA; Ghatge MS; Chowdhury N; Bamane FH; El-Araby ME; Abdulmalik O; Safo MK
Org Biomol Chem; 2015 Jun; 13(22):6353-70. PubMed ID: 25974708
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.
Huang B; Ghatge MS; Donkor AK; Musayev FN; Deshpande TM; Al-Awadh M; Alhashimi RT; Zhu H; Omar AM; Telen MJ; Zhang Y; McMahon TJ; Abdulmalik O; Safo MK
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296435
[TBL] [Abstract][Full Text] [Related]
14. Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.
Deshpande TM; Pagare PP; Ghatge MS; Chen Q; Musayev FN; Venitz J; Zhang Y; Abdulmalik O; Safo MK
Acta Crystallogr D Struct Biol; 2018 Oct; 74(Pt 10):956-964. PubMed ID: 30289405
[TBL] [Abstract][Full Text] [Related]
15. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
16. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
17. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
[TBL] [Abstract][Full Text] [Related]
18. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR
Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300
[TBL] [Abstract][Full Text] [Related]
19. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
[TBL] [Abstract][Full Text] [Related]
20. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.
Kassa T; Strader MB; Nakagawa A; Zapol WM; Alayash AI
Metallomics; 2017 Sep; 9(9):1260-1270. PubMed ID: 28770911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
